Phase I Study of Immune Ablation and CD34+ Peripheral Blood Stem Cell Support in Patients With Systemic Lupus Erythematosus
Unknown
OBJECTIVES: I. Determine the safety of immune ablation with high-dose cyclophosphamide and anti-thymocyte globulin followed by peripheral blood stem cell support in patients with systemic lupus erythematosus.
Gender:
ALL
Ages:
Between 0 years and 59 years
Trial Updated:
06/23/2005
Locations: University of Wisconsin Hospital and Clinics, Madison, Wisconsin
Conditions: Systemic Lupus Erythematosus